Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P61278 (
somatostatin
)
22,083
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of
glucose
, amino acids, pancreozymin-cholecystokinin, and tolbutamide upon the release of immunoreactive
somatostatin
(IRS) from the isolated perfused pancreas were studied. In seven experiments in which
glucose
was perfused either at a concentration of 100 or 350 mg/dl or at 25 mg/dl, IRS levels were significantly greater at the higher
glucose
concentrations. In three dose-response experiments in which the perfusing
glucose
concentration was increased at 30-min intervals from an initial concentration of 25 mg/dl to a final concentration of 300 mg/dl, progressive increases in IRS release were noted at
glucose
concentrations of 100 mg/dl and above. Perfusion of a 20 mM mixture of 10 amino acids also elicited a prompt and significant biphasic IRS rise in each of six experiments. In five experiments, 20 mM leucine evoked a similar response in mean IRS. Perfusion with 0.075 Ivy U/ml of pancreozymin-cholecystokinin, with or without the presence of a 1 mM 10-amino acid mixture, elicited a prompt rise in IRS with a pattern resembling that of insulin in a total of six experiments. Tolbutamide (0.75 mg/min) also stimulated IRS release in five of six challenges. The IRS responses to nutrients and to pancreozymin and their similarity to the insulin responses raise the possibility that, like insulin, pancreatic
somatostatin
may have an endocrine role related to nutrient homeostasis.
...
PMID:Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide. 33 May 67
The effects of
somatostatin
and epinephrine have been studied with regard to
glucose
-induced insulin release and (45)Ca(++) uptake by rat pancreatic islets after 2 days in tissue culture and with regard to (45)Ca(++) efflux from islets loaded with the radio-isotope during the 2 days of culture. (45)Ca(++) uptake, measured simultaneously with insulin release, was linear with time for 5 min. (45)Ca(++) efflux and insulin release were also measured simultaneously from perifused islets.
Glucose
(16.7 mM) markedly stimulated insulin release and (45)Ca(++) uptake.
Somatostatin
inhibited the stimulation of insulin release by
glucose
in a concentration-related manner (1-1,000 ng/ml) but was without effect on the
glucose
-induced stimulation of (45)Ca(++) uptake. Similarly, under perifusion conditions, both phases of insulin release were inhibited by
somatostatin
while no effect was observed on the pattern of (45)Ca(++) efflux after
glucose
.Epinephrine, in contrast to
somatostatin
, caused a concentration-dependent inhibition of the stimulation of both insulin release and (45)Ca(++) uptake by
glucose
. Both phases of insulin release were inhibited by epinephrine and marked inhibition could be observed with no change in the characteristic
glucose
-evoked pattern of (45)Ca(++) efflux (e.g., with 10 nM epinephrine). The inhibitory effect of epinephrine on (45)Ca(++) uptake and insulin release appeared to be mediated via an alpha-adrenergic mechanism, since is was abolished in the presence of phentolamine.
Somatostatin
inhibits insulin release without any detectable effect upon the handling of calcium by the islets. In contrast, inhibition of insulin release by epinephrine is accompanied by a partial inhibition of
glucose
-induced Ca(++) uptake.
...
PMID:Somatostatin- and epinephrine-induced modifications of 45Ca++ fluxes and insulin release in rat pancreatic islets maintained in tissue culture. 33 17
This study was performed in order to evaluate the effects of
somatostatin
on insulin releasing mechanisms and on
glucose
uptake in peripheral tissues using isolated pancreatic islets, isolated rat diaphragms and epididymal fat pads. Insulin release by various concentrations of
glucose
were examined, and it was found that 100 ng/ml of
somatostatin
significantly inhibited insulin release at the
glucose
concentration of 200 mg/dl.
Somatostatin
also significantly inhibted insulin release by the administration of 5microgram/ml of glucagon with 200 mg/dl of
glucose
concentration and 20 mM of orginine with 200mg/dl of
glucose
concentrations. But at the
glucose
concentration of 50mg/dl, no significant inhibition of
somatostatin
on insulin release was observed even when various concentrations of glucagon or arginine were added. The influence of
somatostatin
on peripheral tissues was examined in vitro, and no significant change on
glucose
uptake compared with the control group was shown in either tissues. The results indicated that
somatostatin
directly inhibited insulin release from rat pancreatic islets but had no effect on
glucose
uptake in peripheral tissues. The inhibitory effect of
somatostatin
on insulin release may act through the common mechanism of both
glucose
and other substances in leading to insulin release.
...
PMID:[Effects of somatostatin on pancreatic isolated islets and peripheral tissues of rats]. 33 84
1. Investigation of the ionic requirements of the in vitro insulin release system, which consists of cod islet plasma membrane and rabbit islet granules incubated at pH 6.5, showed that the presence of Ca(2+) was obligatory for the system to operate.2.
Glucose
-initiated insulin release was as effective in the presence of beta-gamma-methylene ATP, as it was in the presence of ATP. This analogue of ATP is a substrate neither for adenylate cyclase nor for any known animal membrane proteases. The effect of ATP on
glucose
mediated release is allosteric.3.
Glucose
(16 mM)-initiated insulin release was slower than that induced by glucose-6-phosphate (4 mM); 150 and 120 sec, respectively.4. The lag found with
glucose
-mediated insulin release was dependent upon
glucose
concentration. The lower the
glucose
concentration, the longer the lag. With 1 mM
glucose
the lag extended to 30 min.5. Once insulin release was initiated, the rate and amount of insulin release was independent of the
glucose
concentration.6. Pre-incubation of membranes with Ca(2+),
glucose
and ATP prior to the addition of granules, abolished the extended lag that had been obtained with 1 mM
glucose
. Events in the plasma membrane are the major contributor to the generation of the extended lag.7. The
glucose
analogue 5'thio-D-glucose, although not able to release insulin, was shown to compete with
glucose
for the glucoreceptor. By increasing the ratio of analogue to
glucose
the lag time increased. Thus, the lag time is dependent upon the ;effective' external
glucose
concentration.8. The max. amount of insulin released by 4 ng of membrane in the presence of
glucose
(16 mM) was 300 ng. The fact that membranes became refractory to
glucose
after this max. amount of insulin was released showed that recycling of release sites was not taking place in vitro and that granule: granule interactions were not occurring.9. The 120 sec lag before glucose-6-phosphate-initiated release was independent of glucose-6-phosphate concentration. The rate of insulin release with glucose-6-phosphate was concentration dependent.10. Glucose-6-phosphate did not cause further insulin release from a membrane that had released the max. amount of insulin it was capable of in the presence of
glucose
. The addition of tolbutamide (10 mM) to such a membrane did cause insulin release. This suggests that
glucose
and glucose-6-phosphate share a final common pathway.11. Adrenaline and
somatostatin
did not inhibit
glucose
-mediated insulin release.
...
PMID:An in vitro system for studying insulin release: effects of glucose and glucose-6-phosphate. 33 48
Electrophysiological studies of rat islet cells in monolayer culture were undertaken to determine the role of transmembranous ionic fluxes in the inhibitory action of
somatostatin
on insulin release. In the presence of somatotropin release inhibiting factor (SRIF) (2.5 nM), hyperpolarization occured with or without
glucose
(16.6 mM) in the medium. SRIF also inhibited the incidence of
glucose
-induced spike activity. The inhibitory action of SRIF occurred within 5 min and was readily reversible. An increase in extracellular K+ (5-13 mM) or Ca2+ (2.3-4.6 mM) prevented SRIF inhibition of
glucose
-induced electrical activity. The secretory response of cultured islets to
glucose
(16.6 mM) was completely inhibited by SRIF (2.5 nM). The presence of high [Ca2+]o or [k+]o enhanced insulin release in the presence of SRIF and
glucose
. Although phentolamine (5.0 microgram/ml) did not block the inhibition of
glucose
-induced electrical responses by SRIF, it prevented the inhibitory action of epinephrine (0.2 microgram/ml). It is concluded that the primary action of SRIF is to alter transmembranous cationic fluxes, as manifested by hyperpolarization and a decrease in the incidence of spike activity, which may prevent
glucose
from eliciting a normal secretory response.
...
PMID:Somatostatin inhibition of glucose-induced electrical activity in cultured rat islet cells. 33 98
Eight 18-days-postcoitum fetal pancreases were transplanted to isogenic alloxan-diabetic male rats. Some recipients were treated with insulin for seven days immediately after transplantation. Eight animals in both the insulin-treated group and control group were killed 15days after transplantation for morphologic and hormonal studies of the transplanted tissue. Using the morphometric technique of linear scanning, the insulin, glucagon, and
somatostatin
immunocytochemically positive, cell masses of the fetal pancreatic implants were quantitated. The beta cell mass of the implants from the control animals increased roughly eightfold from the time of transplant; insulin treatment resulted in a further two- to threefold increase. The insulin content of the implants increased more than did the beta cell mass, resulting in the fivefold increase in insulin per beta cell. The alpha cell and delta cell masses did not change during the transplant site, the mass of functional beta cells, and the cell-to-cell content of the implanted tissue. These results are discussed in relation to previous quantitative studies of pancreatic islet cell growth. The relationships of the transplant site, the mass of functional beta cell, and the cell-to-cell interaction within the islet to the maintenance of
glucose
homeostasis are also discussed.
...
PMID:Syngeneic transplantation of fetal rat pancreas. II. Effect of insulin treatment on the growth and differentiation of pancreatic implants fifteen days after transplantation. 35 89
The present study was conducted to determine if glucagon release is involved in the hyperglycemic response to epinephrine and isoproterenol in the fasted and fed, unanesthetized rabbit. Epinephrine produced dose-related increases in plasma
glucose
and glucagon levels in fed and fasted rabbits whereas isoprotereol produced modest hyperglycemia without hyperglucagonemia. Infusion of
somatostatin
suppressed epinephrine-induced glucagon release and this was correlated with a 50% reduction in the hyperglycemic response. These data suggest that epinephrine-induced glucagon release is the primary reason for the difference in hyperglycemic activity between epinephrine and isoproterenol in the unanesthetized rabbit.
...
PMID:Catecholamine-induced changes in plasma glucose, glucagon and insulin in rabbits: effects of somatostatin. 36 31
Islets were isolated by mild collagenase digestion and microdissection from rat fetuses 2 days before term and pups 1 or 2 days after birth and their insulin and glucagon secretion studied in vitro. Fetal B cells were stimulated by 16.7 mmol/l
glucose
, 20 mmol/l leucine or 20 mmol/l arginine. Fetal A cells were not affected by
glucose
or leucine, but were significantly stimulated by arginine.
Somatostatin
abolished the effect or arginine on both IRI and IRG output. Neonatal islets proportionally released more insulin and glucagon than their fetal counterparts, but reacted to the tested agents in a similar fashion. During the perinatal period, pancreatic insulin storage increased at a higher rate than that of glucagon. It is concluded that fetal B cells are equipped with sensors to a variety of agents and able to modulate their secretory rate according to the concentration of these agents. A cells are reactive to arginine 2 days before term but do not become
glucose
reactive until several days after birth.
...
PMID:Insulin and glucagon secretion by islets isolated from fetal and neonatal rats. 36 57
Eight 18-316 fetal pancreases were transplanted to syngeneic alloxan diabetic male rats. Some of the recipients were treated with insulin for a 7-day period immediately after transplant. By previously published clinical criteria, three groups of recipients could be identified after reversal of diabetes by the transplanted tissue: insulin-treated rapid reversal; insulin-treated slow reversal; and control (not treated with insulin). Five animals in each group were sacrificed after
glucose
tolerance testing for morphologic and hormonal analysis of the transplanted tissue. The insulin-,glucagon-, and
somatostatin
-positive islet cell masses of the fetal pancreatic implants were quantitated. There was a correlation between the beta cell mass of the implants and the
glucose
tolerance exhibited by the host animals. The rapid response insulin-treated recipients had significantly greater implant beta cell mass and insulin content compared with the other groups. There was no difference in implant alpha cell mass among the groups, but the insulin-treated implants had a significantly greater glucagon content. The delta cell mass of insulin-treated rapid response was less than that of the other two groups. The results are discussed in relation to previously reported morphometric analysis 15 days after transplantation. The relationships of transplanted beta cell mass, beta cell differentiation, transplant site, and cell-to-cell interactions within the transplanted islet to the control of
glucose
homeostasis are also discussed.
...
PMID:Syngeneic transplantation of fetal rat pancreas. III. Effect of insulin treatment on the growth and differentiation of the pancreatic implants after reversal of diabetes. 36 28
Insulin secretion induced by leucine and leucine plus
glucose
from rat pancreatic islets was enhanced by prior treatment with
somatostatin
antiserum as compared with normal rabbit serum in vitro. The results provide evidence that
somatostatin
plays an important role in insulin secretion in rats.
...
PMID:Enhancement of leucine-induced insulin secretion by somatostatin antiserum pretreatment. 37 79
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>